



Perflutren

Revised: December 3, 2018.

CASRN: 76-19-7



Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of perflutren during breastfeeding. Because of the extremely short elimination half-life of perflutren (<2 minutes) from the body, use of perflutren either as albumin microspheres or lipid microspheres is acceptable in nursing mothers.[1] Because of the lack of information, the American College of Radiology states that temporary (~24 hours) pumping and discarding of milk may be considered.[2] However, this recommendation appears to be excessively cautious.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1. Cova MA, Stacul F, Quaranta R et al. Radiological contrast media in the breastfeeding woman: a position paper of the Italian Society of Radiology (SIRM), the Italian Society of Paediatrics (SIP), the Italian Society of Neonatology (SIN) and the Task Force on Breastfeeding, Ministry of Health, Italy. *Eur Radiol.* 2014;24:2012-22. PubMed PMID: 24838733.
2. American College of Radiology Committee on Drugs and Contrast Media. Administration of contrast media to breast-feeding mothers. In, ACR manual on contrast media. 2017;Version 10.3:102-3. Available at: <https://www.acr.org/~/media/37D84428BF1D4E1B9A3A2918DA9E27A3.pdf>

Substance Identification

Substance Name

Perflutren

CAS Registry Number

76-19-7

Drug Class

Breast Feeding

Lactation

Contrast Media

Diagnostic Agents

Fluorocarbons

Gases